U.S. Markets closed

Citius Pharmaceuticals, Inc. (CTXR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.08000.0000 (0.00%)
At close: 4:00PM EDT
2.0700 -0.01 (-0.48%)
After hours: 07:37PM EDT
Sign in to post a message.
  • G
    Gain Money
    The entire world, include CTXR mgt. trust that there is no imminent share dilution except David and few others. Doesn't matter. What matters most are, by Implication, Stem cell for ARDS is progressing well, " Buying E7777 is a win win situation" as BLA application expected "Approval" in April 2022), 12 years sales exclusivity. " Not many Pharm. co. has 2 late/final stage trial products. Implying Mino-lok and E7777. He mentioned again that they invested 26.5m of their own money too. Perhaps just to assure the shareholders.
  • C
    Chris
    Mazur just said no dilution coming. Still cash positive
    Bullish
  • K
    Kevin_P
    $2.00 support still holding through down market. This is likely to start a rise within 2 weeks IMO. Good luck getting this under 2.00 again. I'm still loading up myself.
  • C
    Chris
    Don't forget about tomorrow's interview with Benzinga at 10AM ET
  • J
    JEFE
    Great to see some news out this Friday!

    PR Newswire
    Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021

    Tue, September 14, 2021, 7:06 AM
    In this article:

    Discussion to feature diversified clinical pipeline with five active programs

    CRANFORD, N.J., Sept. 14, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will be joining Benzinga's All Access Show for a 20-minute interview on Friday, September 17, 2021 at 10:10 am ET.

    Investors may tune in to the interview with Citius Chairman Leonard Mazur by visiting Benzinga's livestream channel.

    During the interview, Mr. Mazur will discuss advancements in the Company's late-stage clinical pipeline, including the recent addition of I/ONTAK (E7777), a novel oncology asset with an attractive near-term revenue opportunity and substantially de-risked path to support commercial success.

    About Citius Pharmaceuticals, Inc.
    Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19. For more information, please visit www.citiuspharma.com.
  • A
    Always Right
    CTXR would have to break its 200 day MA to dip into the $1.75 range. More likely (BY FAR) is that we bounce off that 200-day and ride it up the line. I see that as all but inevitable. Indeed, even our 20 day has acted as a support. This stock is gaining its resolve.

    There is no particular reason CTXR should dip low again as there has not been bad news and every day is a day closer to fireworks. I know some of you are waiting for that last, miraculous dip...and I would encourage you to look at the 200-day and use THAT (not your hopes and dreams) as a baseline.

    Stochastic shows some downward potential, but if viewed in the context of the 200-day, well, I just have a lot of conviction that this will bounce very soon.
  • A
    Always Right
    I now own 1/1,000th of CTXR! Yay!
  • W
    Walter
    Anyone have a link for the bazinga interview?
  • T
    Tony
    HC Wainwright Global Investor Conference starts today. Here is the link to their webcast https://journey.ct.events/view/05b7959a-7639-457c-95eb-c7ece3cbe4ed

    If you want tTheyo know more about E7777, then this is the webcast for you. They spend most of the webcast discussing E7777. No new Mino Lok updates. Enrollment above 80%. Recruitment and enrollment are still impacted by Covid.
  • K
    Kevin_P
    Market tanking today. I've been loading up today and I suggest others do the same as 3 straight weeks this has held over $2.00 during some rough market patches.
  • D
    Deuce Simmons
    Just listened to webcast! Very exciting news. This stock will explode when E7777 and Mino-lok hit the market. Other nice drugs in the pipeline. Just have to be patient. I think E7777 may beat Mino-lok to market.
  • Z
    Zeus
    Bank of America getting involved, I like it.
  • Z
    Zeus
    Management appears to have a huge amount of confidence in Mino-Loks success. They imply their plans on funding commercialization of E7777 is with revenue from sales of Mino-Lok. Other than the initial $40mm in cash to Dr Reddy for E7777; they mention "no additional financing is currently necessary"
  • G
    Gain Money
    From all the messages that I've read, I deduced that close to 99% are bullish on CTXR. As a matter of fact, the few, probably not more than 5% that spewed negativities are also bullish, but on a longer term. They are not bearish but they just wanted to buy at a much lower price. Some quoted as low as $1.20. by reasons of possible dilution which I don't think it is imminent. Some trade to lower their average price. It is nothing wrong with that but for those who think the price will go as low as $1.70 or $1.50 again, perhaps you have to wait till the cow comes home. Enjoy the wait.
  • D
    Deuce Simmons
    IMO, Citius acquired another late stage developmental drug that they can cash in on in the next year. Remember this drug E7777 is an improved version of the previously FDA approved drug. The deal allows them to spread out the money payments which should allow for some revenue to start coming in. 2022 is going to be huge for this company if you have the patience to wait. Let’s talk of money to be made. These guys are winners and know what there doing. Just saying……
  • A
    Anthony
    CTCR//Great report on CTXR today at 10:21//Potential 375% to the upside//
  • D
    Deuce Simmons
    Press release from BroadStreet tomorrow morning. I have a feeling this is about CTXR. Announcement below:

    Be Prepared for a Major Announcement from one of Our Regularly Covered Companies that Could Be a Strong Near-Term Catalyst

    Good day everyone,

    The NASDAQ is hovering around its loftiest levels and that may be good news for our members as most of our reports cover small cap companies listed on that exchange. When I look at the NASDAQ over 15,000, I’m reminded that investors want more than to just hold large cap equities, they often want to speculate on small caps that might offer greater returns.

    I believe that is why many of our members are here. We are the newsletter researching those opportunities for you. Watching small cap companies to see where there is value, where shares may be oversold, where a catalyst is happening.

    We don’t operate alone. Our members are the basis for success. We only report opportunity but it’s the actions taken by our members that drives company values of to where they should be. Our group is many thousands strong, and we achieve our goals through common interests.

    We are preparing a report over this holiday weekend on a company most of you know well. The fluctuations in the company share price this year let us know when an opportunity arises, and it’s here. This company has big news. I mean huge news and I’m excited about it.

    Some small cap companies can catapult themselves to a new level with just one catalyst and we think that may have just happened to this company. While I am writing this to you, this company is likely preparing a press release to announce the news. It’s not a secret, the news is already in the public domain, but the company hasn’t talked about it yet.

    Stay tuned and stay informed. We will issue this report on Tuesday, September 7th at market open.

    The Team
  • C
    CR
    Is anybody worried about dilution now that such a large chunk of their last offering must be going towards this deal? I know after their last offering they said their operational costs should be covered until 2023 but now I'm not so sure. Any insight?
  • K
    Kevin_P
    I'm loading up today and for the next month will continue. They just tipped their hand on how the Mino-Lok trial is going IMO and plan to leverage that to expand on E7777 which is already proven while adding another catalyst to their balance sheet!

    "With its substantially completed development work and purified formulation, now is an ideal time to add this near BLA-ready and, we believe, de-risked asset to the Citius pipeline. If approved, we intend to leverage the planned commercial infrastructure being developed for Mino-Lok® to launch E7777, providing Citius with potentially two marketed products in 2024. Our strong balance sheet will enable us to complete the transaction and, based on our current projections, continue to advance our other pipeline programs without requiring additional financing at this time,"
    Bullish
  • C
    Chris
    Couldn't resist any longer. Doubled my stake @ $2.05. I think it's a bit high, so praying for no dilution for awhile. LFG
    Bullish